Erez Aminov Sells 55,410 Shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Stock

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) CEO Erez Aminov sold 55,410 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total value of $77,019.90. Following the transaction, the chief executive officer now owns 1,105,790 shares of the company’s stock, valued at $1,537,048.10. This represents a 4.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

MIRA Pharmaceuticals Stock Performance

Shares of MIRA opened at $1.27 on Friday. MIRA Pharmaceuticals, Inc. has a one year low of $0.51 and a one year high of $5.01. The stock’s fifty day moving average is $1.34 and its 200-day moving average is $1.32. The firm has a market capitalization of $21.03 million, a price-to-earnings ratio of -2.27 and a beta of 3.09.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. Analysts forecast that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MIRA Pharmaceuticals stock. Suncoast Equity Management raised its position in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) by 125.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 90,000 shares of the company’s stock after purchasing an additional 50,000 shares during the quarter. Suncoast Equity Management owned about 0.61% of MIRA Pharmaceuticals worth $117,000 as of its most recent SEC filing. 35.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on MIRA. RODMAN&RENSHAW upgraded MIRA Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Ascendiant Capital Markets initiated coverage on shares of MIRA Pharmaceuticals in a research note on Monday, August 5th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Rodman & Renshaw started coverage on MIRA Pharmaceuticals in a report on Monday, September 30th. They set a “buy” rating and a $17.00 price target on the stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.